lenvatinib plus pembro for arcc - update on the clear study
Published 1 year ago • 360 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
6:49
lenvatinib plus pembrolizumab versus soc for previously treated metastatic colorectal cancer
-
0:49
clear: lenvatinib and pembrolizumab in advanced renal cell carcinoma
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
2:08
clear: lenvatinib and pembrolizumab efficacy in arcc across baseline tumor sizes
-
5:19
lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma
-
5:14
lenvatinib plus pembrolizumab after progression on immune checkpoint inhibitors for metastatic rcc
-
7:05
health-related quality of life with lenvatinib plus pembrolizumab for patients with advanced rcc
-
1:56
checkmate 9er: arcc patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib
-
10:06
lenvatinib and pembrolizumab compared to sunitinib for advanced renal cell carcinoma
-
26:34
latest developments in the treatment of mrcc
-
1:06
leap-011: first-line pembrolizumab plus lenvatinib for uc
-
3:26
extended follow-up from a trial of pembrolizumab plus axitinib for advanced renal cell carcinoma
-
4:55
phase ib/ii trial of combination pd-1 therapy against kidney cancer
-
2:37
lenvatinib/everolimus in refractory mrcc
-
6:00
ramucirumab plus pembrolizumab improves os in advanced nsclc
-
1:14
dr. larkin on lenvatinib plus everolimus in patients with rcc
-
12:35
final study results of keytruda® plus lenvima® for advanced endometrial cancer
-
1:24
phase iii findings for lenvatinib in hcc
-
6:42
the role of lenvatinib in advanced rcc